Northwestern spinout raises $5 million
John Pletz
Chad Mirkin
Northwestern University nanotech researcher and entrepreneur Chad Mirkin has raised $5 million for a new startup.
Stoicheia aims to do for materials science what human genomics has done for drug discovery. It plans to build libraries of materials that would allow companies in industries from chemicals to automobiles to quickly identify candidates for new or better products or ways to improve manufacturing processes.
The Skokie-based company’s technology involves printing millions of tiny metal nanoparticles on a chip, enabling researchers to see how they affect particular chemical reactions under various conditions. The same process, called high-throughput screening, is used in drug discovery, dramatically reducing the time it takes to come up with successful candidates.
Provivi Team
Successfully introducing insect pheromones to control damaging pests, the increased funding will strengthen the capacity for a global roll-out SANTA MONICA, CA, UNITED STATES, December 22, 2020 /EINPresswire.com/ Provivi, Inc. ( Provivi ), an emerging crop protection company using pheromones to protect large acreage row crops from major damaging insects, is pleased to inform the completion of a $45.5M financing round. Vivo Capital, a Palo Alto based investment fund, led the round. Returning shareholders, including Kairos Ventures, Temasek, Pontifax AgTech, Tybourne Capital, Lanx Capital, and Spruce Capital, also participated in the financing. The Series C-2 financing is a new milestone in the growth of our company. It builds upon a very successful year where Provivi achieved several product registrations worldwide and launched our first product commercially in Mexico, said Dr. Pedro Coelho, Co-Founder and CEO of Provivi.
Published: Dec 14, 2020
SALT LAKE CITY (BUSINESS WIRE) Foldax®, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria™ biopolymer mitral surgical heart valve. The company anticipates the first use of its mitral valve in a human will take place in the coming weeks.
The mitral valve is the second of three Tria biopolymer heart valve products in the Foldax portfolio, and addresses a large unmet clinical need based on the prevalence of rheumatic fever worldwide.
The first of the company’s products – an aortic surgical heart valve – is currently enrolling a U.S. clinical study as a result of FDA approval of an expanded study last October. The third valve product is a transcatheter aortic valve replacement (TAVR), which is in the pre-clinical testing phase.
Foldax Receives FDA Approval to Initiate Clinical Study of Biopolymer Mitral Heart Valve SALT LAKE CITY (Business Wire) Foldax®, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval for the company to initiate a U.S. clinical study of its Tria™ biopolymer mitral surgical heart valve. The company anticipates the first use of its mitral valve in a human will take place in the coming weeks.
The mitral valve is the second of three Tria biopolymer heart valve products in the Foldax portfolio, and addresses a large unmet clinical need based on the prevalence of rheumatic fever worldwide.